02197.HK
Clover Biopharmaceuticals, Ltd.
HKSE · Healthcare · Biotechnology · CN
HKD 1.29
−0.39%Year over year
Reported trailing growth
- Revenue
- -99.2%
- EBITDA
- +71.4%
- EBIT
- +69.7%
- EPS
- +191.7%
- Free cash flow
- -5.6%
- Operating cash flow
- -5.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -70.5%
- EBITDA
- +75.8%
- EBIT
- +74.0%
- Net income
- +77.9%
- EPS
- +77.8%
- Free cash flow
- +34.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026